Drug intelligence / Profile preview

TR-399

Development stage: Unknown
Lead developer: Tritech Biopharmaceuticals
Modality: Small Molecules
Administration: Transdermal, Topical

Overview

TR-399 is a transdermal gel formulation of vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor, being developed by Tri-Tech Biopharmaceuticals for the treatment of erectile dysfunction. Unlike oral PDE5 inhibitors, TR-399 is designed for topical application to the skin, aiming to provide localized effect with potentially lower systemic side effects. The formulation contains 5% vardenafil hydrochloride trihydrate. It is intended for once-daily continuous use and has demonstrated the ability to enhance erectile function and sexual behavior in nonclinical animal models without significant skin irritation or phototoxicity.

Brand names: SPONTAN
Other names: topical vardenafil gelvardenafil transdermal

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on TR-399.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR-399.

Explore the full profile